NASDAQ: ANIP · Specialty & Generic Drug Manufacturers

ANI Pharmaceuticals (ANIP) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values ANI Pharmaceuticals (ANIP) at $78.16 a share. The stock last closed at $70.89, which puts the model's fair value 10.3% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. ANI Pharmaceuticals, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$78.16midpoint of 2,000 simulations
Last close$70.89NASDAQ: ANIP
Gap to fair value+10.3%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $67.68 to $78.16 (+15.5%). The multiple the model anchors on moved, lifting the fair value: most of the move.

What the model makes of itThe price of $70.89 is 10.3% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 26 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ANIP?

The calibrated range for ANIP over 63 trading days is $62.93 to $80.33. It sits around the last close, and its width comes from the volatility that ANIP's own options imply (36% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $50.88 to $119.15. In 57% of the simulations the fair value came out above the price the model ran on.

$31.66$220.57
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $78.16. Dashed line: the last close, $70.89.

Faircurve Insights · 14 Nov 2026

Faircurve's model put the fair value of ANI Pharmaceuticals at $78.16 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $67.68, so the fair value moved +15.5%. The model says the multiple it anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $62.72 to $81.91. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It covers the completeness of the inputs, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.

ANI Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets branded and generic pharmaceutical products in the United States and internationally.

The model's overall quality score is 81 out of 100, measured against comparable companies. Three factors stand out. Profitability scores 100, with ROIC of 25.9% against a peer median of 8.7%. Growth quality scores 88, with trailing revenue growth of 43.8% against a peer median of 15.1%. Earnings quality scores 85, with FCF / net income of 1.52x against a peer median of 5.21x. The model compares the company with Alkermes plc (ALKS), which has a fair value of its own on the site, and with several other companies that have no verdict on this date.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ANIP report earnings, and how has the stock reacted?

ANI Pharmaceuticals's next earnings report is scheduled for 26 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 8.4% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ANIP's 30 day implied volatility works out to about 10.4% over one month.

On 10 Nov 2026 ANIP moved 5.1% in one session, against the 2.5% a day that options had priced: 2.1 times the implied size.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ANIP's last 8 reports, ignoring direction, was 6.1%.

0%10%20%no quote7.1%28 Feb '25no quote23.0%8 Aug '25no quote1.4%7 Nov '2514.6%2.5%27 Feb '26no quote6.2%8 May '26no quote8.3%7 Aug '269.8%5.9%5 Nov '268.0%2.6%6 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ANIP

5%10%15%20%6 Nov '26 report5 Nov '26 report7 Aug '26 report8 May '26 report27 Feb '26 report10% at 16 Nov '2622 Dec '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 14% on 22 Dec 2025, reached 16% on 8 May 2026 and reads 10% on 16 Nov 2026. The marks are report dates.

How does ANIP score on business quality?

ANI Pharmaceuticals's overall quality score is 81 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10025.9%ROIC8.7%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).851.52xFCF / net income5.21x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.8843.8%Revenue growth, trailing15.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.491.8%Net buybacks / market value1.8%
Balance sheetNet debt to EBITDA and interest coverage.74-0.45xNet debt / EBITDA2.00x
StabilityDownside volatility of the EBITDA margin over the last five years.425.8 ptsEBITDA margin downside volatility, 5y5.4 pts

How does ANIP compare with similar companies?

The companies in specialty & generic drug manufacturers closest to ANI Pharmaceuticals in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
SUPN Supernus, Inc.$28.83$29.86+3.6%Low evidence grade
PAHC Phibro Animal Health Corporation$35.02$36.25+3.5%Low evidence grade
PCRX Pacira BioSciences, Inc.$36.48$36.71+0.6%Low evidence grade
AMPH Amphastar Pharmaceuticals, Inc.$29.17$29.56+1.3%Low evidence grade
COLL Collegium Pharmaceutical, Inc.$25.43$25.54+0.4%Low evidence grade
LNTH Lantheus Holdings, Inc.$101.72$100.47-1.2%Data under review
AMRX Amneal Pharmaceuticals, Inc.$21.23$19.34-8.9%Low evidence grade
ALKS Alkermes plc$46.53$46.510.0%Fairly valued

What the comparable companies' multiples alone would give for ANIP, the peer-implied price, is $114.08 a share on this run. The fair value weighs that against the company's own multiple.

All specialty & generic drug manufacturer stocks ranked by gap to fair value

ANI Pharmaceuticals at a glance

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Market value
$1.6B
Sector
Healthcare
Industry
Specialty & Generic Drug Manufacturers
Revenue expected, next twelve months
$1.2B
Consensus revenue growth, next fiscal year
+24.3%
Analysts with estimates
4
Beta to the US market
0.21
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ANIP was among them.

How the fair value is worked out: the model prices ANI Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ANIP was $67.68. As of 14 Nov 2026 it is $78.16, a change of +15.5%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about ANI Pharmaceuticals's valuation

Is ANI Pharmaceuticals stock undervalued or overvalued?

On Faircurve's model, ANIP reads as Fairly valued as of 14 Nov 2026. The model's fair value is $78.16 a share against a last close of $70.89, a gap of +10.3%.

What is ANIP's fair value?

$78.16 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $50.88 to $119.15.

What price range does the model give ANIP?

$62.93 to $80.33 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does ANI Pharmaceuticals report earnings next?

The next report is scheduled for 26 Feb 2027. Companies can move their dates.

How much has ANIP moved on past earnings reports?

Across its last 8 reports the median two session move was 6.1%, ignoring direction. The largest was +23.0% around the report of 8 Aug 2025.

How confident is the model in this valuation?

The model's evidence grade for ANIP is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ANIP

The model holds no idea open on ANIP today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ANIP with their outcomes. A free account is enough.

Keep reading